Compare NTZ & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTZ | NRXS |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 25.8M |
| IPO Year | 1993 | 2023 |
| Metric | NTZ | NRXS |
|---|---|---|
| Price | $2.52 | $3.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 8.8K | ★ 854.7K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $358,555,673.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | N/A | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $2.15 | $1.33 |
| 52 Week High | $5.50 | $6.20 |
| Indicator | NTZ | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 68.15 |
| Support Level | $2.24 | $2.63 |
| Resistance Level | $2.69 | $4.25 |
| Average True Range (ATR) | 0.21 | 0.33 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 49.29 | 75.43 |
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).